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Background: Chronic obstructive pulmonary disease (COPD) has been associated with periodontal disease (PD),
and periodontal treatment (PT) has been connected to reduction of lung disease exacerbations. Bronchiectasis has
many clinical similarities with COPD but, although it is also a chronic lung disease, to date it has not been studied
with relation to PD. The aim of this study is to evaluate whether PT associated with photodynamic therapy (PDT)
reduces the number of exacerbations, improves pulmonary function, periodontal clinical parameters and quality of
life after 1 year of periodontal treatment follow-up.
Methods: Bronchiectasis patients will undergo medical anamnesis and periodontal examination. Participants with
periodontitis will be divided into two groups and PT will be performed as G1 control group (n = 32) – OHO (oral
hygiene orientation) + supragingival treatment + simulation of using photodynamic therapy (PDT); G2 experimental
(n = 32) – scaling and root planing + PDT + OHO. Lung function will be assessed both at baseline and after 1 year
by spirometry, exacerbation history will be analyzed through clinical records monitoring. Three instruments for
quality of life assessment will also be applied – Saint George’s Respiratory Questionnaire and Impact Profile Analysis
Oral health (OHIP-14). It is expected that periodontal treatment can improve the analyzed parameters after 1 year.
Discussion: Although only one study evaluates exacerbation in COPD after 1 year of PT, bronchiectasis has not
been studied in the dentistry field to date. Trial registration: NCT02514226. Version #1. This study protocol receives
grant from FAPESP (São Paulo Research Foundation) #2015/20535-1. First received: July 22, 2015, 1st version. This
protocol has been approved by the Research Ethics Committee of Nove de Julho University.
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In recent years, many studies have associated periodon-
tal disease (PD) and pulmonary diseases [1]; they have
also connected decreased lung function to loss of peri-
odontal attachment [2]. Chronic obstructive pulmonary
disease (COPD) is the most studied lung disease related
to PD. The pathophysiological process linking both con-
ditions is the destruction of connective tissue and exac-
erbated inflammatory reaction with large recruitment of
neutrophils [3]. In 1 year, periodontal treatment (PT)
was able to reduce annual number of COPD exacerba-
tions from 9 to 4 [4].
Bronchiectasis is also a chronic, irreversible lung dis-
ease characterized by permanent bronchi dilation. How-
ever, it has not yet been studied in the dental field. It is a
condition that causes high morbidity, affecting patients’
quality of life [5]. In Brazil, its prevalence is estimated at
4–18% [6]. Many health professionals are not familiar
with its diagnosis and, hence, it is often diagnosed as
asthma or COPD due to similarities in clinical manifes-
tations [7], such as cough and sputum production [8].
Bronchiectasis patients suffer with recurrent acute exacer-
bations, which sometimes require hospitalization, increas-
ing public health expending. These patients exacerbate an
average of 6.6 times per year [7] and clinical treatment is
based on prevention and control of exacerbation episodes,
leading to decreased number of hospitalizations.
The etiology of bronchiectasis is extremely heteroge-
neous and may involve genetic as well as acquired
causes. The pathophysiology of bronchiectasis develop-
ment involves mucociliary changes that result in bacterial
colonization and subsequent chronic inflammation with
damage to the bronchi [9]. Periodontal pathogens have
been found in infected lung fluid [10–12]. Thus, there is
biological plausibility in the assertion that a decrease in
oral bacterial load could reduce the number of pulmonary
exacerbations [5, 6]. To confirm this data, it is essential to
measure PT contribution in improving bronchiectasis pa-
tients’ quality of life.
Hence, clinical randomized controlled trials are neces-
sary to test if the reduction in oral infection decreases
the number of exacerbations [13]. So, the hypothesis of
this study is that periodontal treatment can reduce epi-
sodes of bronchiectasis exacerbation and improves bron-
chiectasis patients’ quality of life after 1 year. Therefore,
the aim of this study is to determine if periodontal treat-
ment leads to fewer episodes of bronchiectasis exacerba-
tion and improves bronchiectasis patients’ quality of life
after 1 year.
Methods
A randomized, controlled, 12-month, parallel-group clinical
trial, registered at www.clinicaltrial.gov (NCT02514226) will
be performed. After verbal and written explanation of thestudy, patients will sign the Informed Consent Form ap-
proved by the Research Ethics Committee (# 1.057.901)
Universidade Nove de Julho (UNINOVE). A researcher not
involved in the study will enroll patients. Forty patients
under medical care at InCor-FMUSP with generalized
chronic periodontitis will receive periodontal treatment at
Universidade Nove de Julho’s Dental Clinic, from August
2016 to September 2018.
Sample size calculation
For this study, based on exacerbations of bronchiectasis,
we assume that the difference between the groups will
be one exacerbation with a standard deviation of 1.4
[14] with an effect size of 1. Thirty-two (32) patients per
group will be necessary with a significance level of 5%, a
power of 80% in a two-group t-test, using the statistical
package Dell Statistica version 12.
Inclusion and exclusion criteria
Patients ≥35 years, of both genders, clinically stable with
more than 10 teeth and chronic moderate periodontal
disease, i.e., more than 15% of examined teeth with
≥4 mm probing depth (PD) will be included [8]. Patients
will be included if they have bronchiectasis, character-
ized clinically by chronic sputum production and dilated
bronchi, and confirmed by chest computed tomography
scan. Severity of bronchiectasis will be assessed accord-
ing to FACED score [14].
Smokers or former smokers who have quit for less
than 5 years will be excluded. Also, pregnant women,
patients with other lung diseases, such as cystic fibrosis,
COPD and asthma, those who are taking medications
that affect periodontal condition (e.g., phenytoin or
cyclosporine), patients with decompensated systemic
diseases, those who required prophylactic antibiotic
therapy before periodontal treatment or those who have
undergone periodontal treatment less than 6 months
prior will be excluded.
Anamnesis and physical examination
In the anamnesis, questions will be asked about the pa-
tients’ general health. Demographic data (age, gender,
marital status, occupation, educational level, living condi-
tions and salary) will be collected, as well as medical his-
tory data (main complaint, current state of illness, medical
and dental history, and medication use), habits and addic-
tions (smoking, drinking, nutrition and oral hygiene).
On physical examination, clinical periodontal parame-
ters will be collected by a single researcher. The calibra-
tion will be performed by a single researcher at six sites
per tooth for probing depth (PD) and clinical attachment
level (CAL) according to Pinto et al. (2016) [8]. The data
will undergo the intraclass correlation coefficient test –
Fig. 1 Flow chart summarizing the experimental design
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be >80%.
This researcher will not be involved in the periodontal
treatment of bronchiectasis patients. The following peri-
odontal parameters will be evaluated: probing depth
(PD), clinical attachment level (CAL), gingival index
(GI), visible plaque index, probing bleeding (SS) and
suppuration (S) (Ainamo, Bay 1975) [16].
Three questionnaires will be used to assess bronchiec-
tasis patients’ quality of life: Saint George’s Respiratory
Questionnaire – SGRQ, CoLB, and OHIP-14. They will
be applied at baseline and after 12 months after peri-
odontal treatment (Fig. 1).Analysis of Oral Health Impact Profile (OHIP-14
questionnaire)
The Oral Health Impact Profile (OHIP-14) is a simplified
form of the original questionnaire OHIP used for assess-
ment of oral health impact on quality of life [17]. Items
are distributed among the following subscales: functional
limitation, pain, psychological discomfort, physical disabil-
ity, psychological disability, social disability, and deficit.Saint George’s Respiratory Questionnaire – SGRQ
The specific Saint George’s Respiratory Questionnaire
(SGRQ) is used to assess quality of life in patients with
pulmonary disease [18]. Responses will be evaluated by
two experienced physiotherapists (S.D.C. and F.D.C.) that













Anamnesis (epidemilogical data) and physical examination x
Periodontal clinical examination x
Analysis of Oral Health Impact Profile (OHIP-14 questionaire) x
Saint George’s Respiratory Questionaire–SGRQ x
Quality of Life Questionaire–Bronchiectasis (QoL–B) x
Spirometry xSpirometry
Spirometry tests will be performed by two physiothera-
pists (S.D.C. and F.D.C.) using ULTIMA CPX (Med-
Graphics Corporation®, St. Paul, MN, USA) with a
calibrated pneumotachograph. The technical procedures,
acceptance criteria and reproducibility are recom-
mended by the Brazilian Consensus on Spirometry [7].
All patients will perform this procedure after using a
bronchodilator (salbutamol 400 μcg inhalation). Vari-
ables recorded include FVC (forced vital capacity), FEV1
(forced expiratory volume in one second timed) and
FEV1/FVC. The values will be expressed in absolute
values and percentage of the predicted for the Brazilian
population [12].Randomization
Randomization will be performed as described by Pinto
et al. (2016) [8] using Microsoft Excel, version 2013.
Forty patients will be randomly distributed into experi-
mental and control groups. The randomization will be
blocked in groups of four patients.
Opaque envelopes will be identified with sequential
numbers and inside of each of them a sheet will be
inserted containing the corresponding group information,
according to the random order obtained. The envelopes
will be sealed and remain sealed in numerical order in a
safe place until the time of periodontal treatments.
Patients will be allocated into experimental and con-
trol groups as follows:collection
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hygiene orientation) + supragingival treatment +
simulation of using photodynamic therapy (PDT)
 Group 2 – experimental (n = 32) – scaling and root
planning + PDT +OHO (Table 1).
Photodynamic therapy (PDT)
Patients of Group 2 will receive photodynamic therapy.
PDT associates a photosensitizer with light source in
order to reduce the microbial load. The procedures will
be performed as described.
 Scaling and root planning
 Application of methylene blue (0.005% - Chimiolux
10, DMC® – Purified water and methylene blue)
with a carpule syringe and needle (with stop and
without bevel) into the periodontal pockets >4 mm
 Wait for 3 min (Betsy [19])
 Irradiation will be performed with red laser diode
(λ = 660 nm) with an output power of 100 mW
(MM Optics Twin Laser, São Paulo, SP, Brazil) in all
sites around a tooth (six sites per tooth) on all teeth,
lastly, 1 min irradiation scanning around each tooth.
 Washing abundantly with saline until complete
removal of methylene blue
Every adverse effects will be related.
Blinding
Patients of control group will receive simulation of using
photodynamic therapy (PDT).
The simulation of PDT will be performed by applying
methylene blue (0.005% - Chimiolux 10, DMC® – Purified
water and methylene blue) with a carpule syringe and nee-
dle (with stop and without bevel) into the periodontal
pockets >4 mm. Then, wait for 3 min (Betsy [19]). Irradi-
ation will be performed with the laser (MM Optics Twin
Laser, São Paulo, SP, Brazil) turned off in all sites around a
tooth (six sites per tooth) on all teeth, lastly, 1 min irradi-
ation scanning around each tooth. Than, the operator will
wash abundantly with saline until complete removal of
methylene blue.
Statistical analysis
The Liliefors test will assess the normality of the data. If
the data are normal, t test (Bioestat 5.3, Pará, Brazil) will
be used to compare continuous and dependent variables
of Groups 1 and 2 (periodontal parameters). If the data do
not have normal distribution, Mann Whitney test will be
used. Baseline data will be compared with data from
12 months after treatment. The value of p <0.05 will be
considered statistically significant. The x2 test will be used
to compare categorical variables between Groups 1 and 2.
All values will be expressed as mean ± Standard Deviation.Study variables
The primary variable of the study will be the number of
exacerbations. Secondary variables will include spirom-
etry (lung evaluation), dental clinical parameters (peri-
odontal examination), and quality of life parameters
(SGRQ, and OHIP-14 questionnaires). These variables
will be assessed at baseline and 12 months after peri-
odontal treatment.
Strategies for achieving adequate participant enrolment
to reach target sample size
Patients will be evaluated every 3 months in order to
motivate and hygiene control.
Discussion
Lung diseases, such as chronic obstructive pulmonary
disease (COPD) and bronchiectasis, cause impairment to
a patient’s quality of life with large numbers of comor-
bidities. It has been shown that periodontal treatment
(PT) and oral hygiene (OH) deceases the severity of
COPD [4]; but, despite clinical and pathophysiological
similarities between COPD and bronchiectasis [20],
there is no study to date about the relationship of bron-
chiectasis with periodontal disease (PD). Patients with
bronchiectasis have multiple episodes of disease exacer-
bations. Interventions, such as physical exercises and
chronic administration of certain drugs decrease the
number of such occurrences, but no intervention can
achieve results within less than 6 months [21–30]. In
this study, we will perform an oral intervention with a 1-
year follow up. We will measure the number of exacer-
bations, spirometry data, dental clinical parameters and
quality of life parameters (SGRQ, and OHIP-14 ques-
tionnaires). Saint George’s Respiratory Questionnaire is
the most complete instrument, considered the gold
standard for lung diseases, and OHIP-14, which analyze
the impact of oral health profile. It is expected that peri-
odontal treatment maintained for 1 year will help reduce
the number of exacerbations, improve lung mechanics
and quality of life in bronchiectasis patients.
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